Replies to post #241050 on Biotech Values

[willyw]

Dew, great to see your thinking on these.
I opened a small Pardes holding today since it was a covid related stock (as are ENTA and PFE) and there was a more attractive buy in point today.
It's a hedge, but also a means of forcing myself to better track ENTA competition.

I note that PRDS already have a follow on pre-clinical covid drug.
It seems a positive that PRDS is ahead of ENTA in covid trials-
- yet it seems positive for ENTA that PARDES already is in the works to improve upon their PI.

[DewDiligence]

ENTA 2022 newsflow:

https://www.enanta.com/investors/news-releases/press-release/2022/Enanta-Pharmaceuticals-to-Provide-Updates-on-its-Research-and-Development-Programs-and-Outlook-for-2022-at-the-40th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx

• EDP-235 phase-1 starting Feb 2022. (EDP-235 is a SARS-CoV-2 protease inhibitor.)

• Phase-2 ‘RSVP’ data for EDP-938 in 2Q22.

• EDP-323 (RSV L-protein inhibitor) phase-1 starting 2H22.

[bladerunner1717]

• ASMB 5%: Well-funded and trading for only 65% of cash value! HBV program has been unimpressive, but they might get lucky.

Dew, AMSB now trading at less than 50% cash value. Folks from Gilead in key management positions. Do you see much value in the pipeline?


Bladerunner

[DewDiligence]

SPEX.SW 4Q21 results:

https://spexisbio.com/news-adhoc/news-detail/?newsid=2221723
https://www.webcast-eqs.com/spexis20220324

This is the first quarterly CC for the merged company.

[DewDiligence]

Barron’s likes BMY on valuation:

https://www.barrons.com/articles/buy-bristol-myers-stock-pick-51653520520

…simply getting back to its five-year average [P/E] multiple of 11.7 times would put Bristol stock at $91.38…while getting to Merck’s 13 times would put the shares at $101.53…

BMY's performance in 2022 YTD has been pretty good, but the stock is still cheap.

[swampboots]

DTIL: new lows $1.32 near Yahoo stat of $1.13 book value, what am I missing?